Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies

Priscila Oliveira de Lima; Shannon Joseph; Benedict Panizza; Fiona Simpson

doi:10.1007/s11864-019-0697-3

Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies

Curr Treat Options Oncol. 2020 Feb 3;21(1):9. doi: 10.1007/s11864-019-0697-3.

Authors

Priscila Oliveira de Lima¹, Shannon Joseph¹, Benedict Panizza^{2

3}, Fiona Simpson⁴

Affiliations

¹ The University of Queensland Diamantina Institute, University of Queensland, Woolloongabba, Queensland, Australia.
² Faculty of Medicine, University of Queensland, Woolloongabba, Queensland, Australia.
³ Otolaryngology-Head and Neck Surgery Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
⁴ The University of Queensland Diamantina Institute, University of Queensland, Woolloongabba, Queensland, Australia. f.simpson@uq.edu.au.

PMID: 32016630
DOI: 10.1007/s11864-019-0697-3

Abstract

Recent studies have evidenced the potential of combining anti-EGFR therapies with anti-PD-1/PD-L1 checkpoint therapies. Both anti-EGFR and anti-PD-1/PD-L1 have been separately tested in the treatment of cutaneous SCC (cSCC). Here, we review recent data on EGFR in the context of cancer progression, as a prognostic and as a therapeutic target in cSCC. Anti-EGFR/checkpoint immunotherapy and other combination therapy approaches are discussed. With the advent of immunotherapy, EGFR is still a valid cSCC target.

Keywords: Epidermal growth factor receptor (EGFR); Programmed death ligand 1 (PD-L1); Squamous cell carcinoma (SCC); Therapy.

Publication types

Review

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use
Biomarkers, Tumor*
Carcinoma, Squamous Cell / drug therapy
Carcinoma, Squamous Cell / etiology*
Carcinoma, Squamous Cell / metabolism*
Carcinoma, Squamous Cell / pathology
Clinical Trials as Topic
Disease Management
Disease Susceptibility
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
ErbB Receptors / metabolism
Humans
Immune Checkpoint Proteins / genetics
Immune Checkpoint Proteins / metabolism
Immunotherapy
Molecular Targeted Therapy
Prognosis
Skin Neoplasms / drug therapy
Skin Neoplasms / etiology*
Skin Neoplasms / metabolism*
Skin Neoplasms / pathology
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor
Immune Checkpoint Proteins
EGFR protein, human
ErbB Receptors